Replicel Life Sciences is Drug Discovery in Canada that focus on Life Sciences Inc business. Founded in 1967. They cover business area such as RepliCel Life Sciences Inc, autologous cell therapy, functional cellular deficit, various disease, chronic tendon injury, androgenetic alopecia, skin aging, its development program, distinct technology, dermal injection, dermal filler product, Licensing fee.
1967
( 57 years old in 2024 )
Life Sciences Inc
-
570 Granville Street
Suite 900
Vancouver, British Columbia V6C 3P1
Canada
Private
RepliCel Life Sciences Incautologous cell therapyfunctional cellular deficitvarious diseasechronic tendon injuryandrogenetic alopeciaskin agingits development programdistinct technologydermal injectiondermal filler productLicensing fee
* We use standard office opening hours in near Replicel Life Sciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Replicel Life Sciences is Drug Discovery business from Canada that founded in 1967 (57 years old in 2024), Replicel Life Sciences business is focusing on Life Sciences Inc.
Replicel Life Sciences headquarter office and corporate office address is located in 570 Granville Street Suite 900 Vancouver, British Columbia V6C 3P1 Canada.
Replicel Life Sciences was founded in Canada.
In 2024, Replicel Life Sciences is currently focus on Life Sciences Inc sector.
Above is snippet of Google Trends for "Life Sciences Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Replicel Life Sciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
